What is the 13F Pro Quality Score for VYGR?

13F Pro ranks Voyager Therapeutics, Inc. (VYGR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VYGR's current score at https://13fpro.ai/research/VYGR (free sign-up required for the full ranking).

Which hedge funds own the most VYGR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VYGR include BlackRock,, ARMISTICE CAPITAL,, MILLENNIUM MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VYGR as soon as new 13F filings post.

Where does 13F Pro source VYGR data?

All Voyager Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Voyager Therapeutics, Inc. files with the SEC under CIK 1640266. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VYGR in?

Voyager Therapeutics, Inc. (VYGR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VYGR research updated on 13F Pro?

VYGR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Voyager Therapeutics, Inc.(VYGR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1640266 VYGR stock profile & AI dashboard →

13F Pro Quality Score

5.5/100

Rank #2,847 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

0.5/100

Profitability

3.7/100

Balance Sheet

3.6/100

Earnings Quality

30.0/100

Free Cash Flow

3.1/100

Institutional Flow

17.7/100

Revenue Scale

6.7/100

Dilution Risk

5.5/100

VYGR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Voyager Therapeutics, Inc. (VYGR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VYGR at 5.5/100 on a 32-signal composite quality model, placing it at rank #2,847 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.5) and free cash flow (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Voyager Therapeutics, Inc. reports quarterly revenue of $2.6M, net income of $-27.9M, free cash flow of $-33.4M. Top institutional holders of VYGR by reported 13-F value include BlackRock,, ARMISTICE CAPITAL,, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. VYGR trades on the Nasdaq exchange and files with the SEC under CIK 1640266. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VYGR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Voyager Therapeutics, Inc. directly from SEC EDGAR. Voyager Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 79 since 2021, currently 5.5 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Voyager Therapeutics, Inc.

Quirks, history, and lore behind VYGR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Cambridge, Massachusetts · focused on the central nervous system.
2
The Numbers
Like most clinical-stage biotechs, it generates minimal product revenue and relies on partnerships and grants to fund its research pipeline — the balance sheet is more runway than revenue.
3
The History
Founded in the 2010s, it was built around a proprietary gene therapy platform targeting devastating neurological diseases that have few or no approved treatments.
4
The Secret
Its core technology uses adeno-associated viruses (AAV) as delivery vehicles — essentially biological UPS trucks engineered to drop therapeutic genes directly into brain cells.
5
The Lore
The company has pursued gene therapies for conditions like Parkinson's disease and Huntington's disease, partnering with major pharma players to push its programs toward the clinic.
6
The Giveaway
Its name evokes deep-space exploration, its ticker is VYGR, and its mission is equally ambitious: rewriting the genetic code of the brain to cure diseases once thought untreatable.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$2.6M

Net Income

Q1 2026

$-27.9M

Free Cash Flow

Q1 2026

$-33.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-46.8% YoY

$80.0MFY 2024

FY21 $37.4MFY22 $40.9MFY23 $150.5MFY24 $80.0M

Net Income

-149.1% YoY

$-65.0MFY 2024

FY21 $-71.2MFY22 $-46.4MFY23 $132.3MFY24 $-65.0M

Operating Income

-168.3% YoY

$-83.3MFY 2024

FY21 $-73.6MFY22 $-50.8MFY23 $122.0MFY24 $-83.3M

EPS (Diluted)

-138.0% YoY

$-1.13FY 2024

FY21 $-1.89FY22 $-1.21FY23 $2.97FY24 $-1.13

Total Assets

+11.9% YoY

$393.1MFY 2024

FY21 $193.9MFY22 $159.4MFY23 $351.3MFY24 $393.1M

Op. Cash Flow

-119.6% YoY

$-15.3MFY 2024

FY21 $-53.5MFY22 $-12.5MFY23 $77.9MFY24 $-15.3M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$80.0M -46.8%	$150.5M +267.9%	$40.9M +9.3%	$37.4M -78.1%	$171.1M +2146.1%	$7.6M
Net Income	$-65.0M -149.1%	$132.3M +385.1%	$-46.4M +34.8%	$-71.2M -293.8%	$36.7M +141.6%	$-88.3M
Operating Income	$-83.3M -168.3%	$122.0M +340.0%	$-50.8M +30.9%	$-73.6M -368.8%	$27.4M +130.1%	$-91.1M
EPS (Diluted)	$-1.13 -138.0%	$2.97 +345.5%	$-1.21 +36.0%	$-1.89 -292.9%	$0.98 +135.6%	$-2.75
Total Assets	$393.1M +11.9%	$351.3M +120.4%	$159.4M -17.8%	$193.9M -25.9%	$261.6M +47.8%	$177.0M
Operating Cash Flow	$-15.3M -119.6%	$77.9M +722.9%	$-12.5M +76.6%	$-53.5M +44.7%	$-96.7M -508.8%	$-15.9M

AI Insight: VYGR Financial Trends

Equity has eroded 48% from $335M to $174M over eight quarters as VYGR burns cash with no path to operating profitability visible in the data.

• Revenue collapsed from $30M in Q2 2024 to $3M in Q1 2026, with no quarter of sequential recovery sustained.

• Operating losses remain stubbornly wide: op income ranged from -$14M to -$38M across all eight quarters with no meaningful improvement.

• Equity has declined every quarter, falling from $335M in Q2 2024 to $174M in Q1 2026 — a $161M reduction.

• Operating cash outflows averaged roughly -$30M per quarter, suggesting less than two years of runway at current burn if equity approximates cash.

⚠ Equity fell to $174M in Q1 2026; at ~$30M quarterly burn, runway is finite — next capital raise terms will be critical.

⚠ Revenue ticked up to $13M–$15M in Q3–Q4 2025 before dropping back to $3M in Q1 2026 — watch whether any partnership milestone can stabilize revenue.

⚠ No debt is reported across all periods; any shift to debt financing would signal accelerating balance-sheet stress.

AI Insight: VYGR Ratio Trends

VYGR's return metrics have deteriorated sharply, with ROIC plunging from -16.7% in Q3 2024 to -73.4% on a TTM basis.

• ROIC worsened from -16.7% in Q3 2024 to -61.1% in Q4 2025, reflecting deepening capital inefficiency over five quarters.

• Operating margin collapsed to -195.2% in Q4 2025 from -56.0% in Q3 2024, suggesting a significant one-off cost event.

• ROA deteriorated from -8.5% in Q3 2024 to -53.2% on a TTM basis, indicating rapidly eroding asset productivity.

⚠ Q4 2025 operating margin of -195.2% is a severe outlier; confirm whether a one-time charge drove this or if it reflects ongoing burn.

⚠ D/E data is absent throughout; without leverage visibility, balance sheet stress from continued losses cannot be fully assessed.

Get alerted when VYGR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Voyager Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VYGR

BlackRock, Inc.
$21.5M5,568,381 sh
ARMISTICE CAPITAL, LLC
$13.5M3,500,000 sh
MILLENNIUM MANAGEMENT LLC
$13.2M3,428,571 sh
Vestal Point Capital, LP
$11.6M3,002,936 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.8M2,283,253 sh
Opaleye Management Inc.
$4.4M1,150,000 sh
Erste Asset Management GmbH
$4.2M1,095,141 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.1M1,049,978 sh
STATE STREET CORP
$3.7M948,226 sh
DIMENSIONAL FUND ADVISORS LP
$3.4M875,568 sh

Fund	Value	Shares
BlackRock, Inc.	$21.5M	5,568,381
ARMISTICE CAPITAL, LLC	$13.5M	3,500,000
MILLENNIUM MANAGEMENT LLC	$13.2M	3,428,571
Vestal Point Capital, LP	$11.6M	3,002,936
VANGUARD CAPITAL MANAGEMENT LLC	$8.8M	2,283,253
Opaleye Management Inc.	$4.4M	1,150,000
Erste Asset Management GmbH	$4.2M	1,095,141
GEODE CAPITAL MANAGEMENT, LLC	$4.1M	1,049,978
STATE STREET CORP	$3.7M	948,226
DIMENSIONAL FUND ADVISORS LP	$3.4M	875,568

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VYGR on your watchlist

Track score changes the day Voyager Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VYGR a good stock to buy?

13F Pro's AI-powered analysis of Voyager Therapeutics, Inc. (VYGR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VYGR are available on the VYGR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VYGR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VYGR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Voyager Therapeutics, Inc.'s investment landscape.